Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Blood-Saving technique could transform liver surgery

NCT ID NCT07629648

Disease control Sponsor: Dr. Glenio Mizubuti (MD, PhD, FRCPC) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a controlled blood removal method during liver surgery to see if it lowers the need for blood transfusions. About 60 adults having liver resection for cancer will take part. The approach involves removing a small amount of blood before surgery and giving it back afterward, along with careful monitoring and standardized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hypovolemic phlebotomy (controlled blood removal and reinfusion)
What this could lead to
If successful, this could reduce the need for blood transfusions during liver surgery, leading to fewer complications and faster recovery.
What could go wrong
This is a small, early-stage quality improvement project with only 60 participants. The approach may not work for all patients or may carry risks like unstable blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged ≥18 years undergoing elective hepatic resection at Kingston Health Sciences Centre.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Liver resection in this study is defined according to the PRICE-2 trial, involving 3 or more liver segments, such as right posterior sectionectomy (of segments VI and VII) as well as central resections involving segments IVb and V, along with expected blood loss of \>250 mL * in patients with known liver cirrhosis, resection of a full segment was included. Exclusion Criteria (defined according to the PRICE-2 trial): * current cardiac condition (e.g., MI within the last 6 months, hypertrophic cardiomyopathy, severe valvular disease, or other unstable coronary syndromes) * history of cerebrovascular disease (CVA within the past 6 months or severe carotid stenosis with more than 70% occlusion) * history of significant peripheral vascular disease (not yet revascularized with regular/ongoing claudication) * A current pregnancy * A documented, patient-declared refusal to undergo phlebotomy and transfusion * preoperative autologous blood donation * presence of active infection * preoperative hemoglobin \<100 g/L * GFR \<60 mL/min * platelets count \<100 × 109/L * Uncorrectable coagulopathies or other decompensated cardiac or respiratory conditions that would contraindicate acute volume depletion * undergoing emergency surgery * planned intraoperative use of cell salvage * inability to participate in follow up * in the case of repeat liver resections, previous participation in the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood cells transfusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Blood Loss, Surgical cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood cells transfusion Hepatectomy Intraoperative bleeding Intraoperative monitoring Phlebotomy Transfusion requirements

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.